Freedom of Information request on the follow up questionnaire documents for Gilenya 0.5mg hard capsules from Novartis Europharm Limited (FOI 22/779)
Published 21 December 2023
© Crown copyright 2023
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-20-june-2022/freedom-of-information-request-on-the-follow-up-questionnaire-documents-for-gilenya-05mg-hard-capsules-from-novartis-europharm-limited-foi-22779
FOI 22/779
24th June 2022
Dear
Thank you for your email, dated 23rd June 2022, in which you requested:
‘the Follow up-Questionnaire documents’ for Gilenya 0.5mg hard capsules from Novartis Europharm Limited.
A copy of the information, which can be disclosed, is attached.
As per the instruction of the MAH, no information has been redacted from the attached file.
I hope the information provided is helpful; however, if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Please remember to quote the reference number above in any future communications.
Yours sincerely,
FOI Team,
Vigilance and Risk Management of Medicines Division